HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.88 CAD | +0.78% | -6.28% | -1.77% |
09/05 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.77% | 9.01Cr | |
+20.97% | 7.25TCr | |
-4.65% | 2.34TCr | |
+4.16% | 857.18Cr | |
+9.26% | 828.53Cr | |
-24.53% | 764.15Cr | |
+13.31% | 522.86Cr | |
0.00% | 416.68Cr | |
+6.13% | 397.47Cr | |
-1.31% | 393.18Cr |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024